SSKN · As filed with the SEC
STRATA Skin Sciences cash flow statement, by fiscal year
The statement as STRATA Skin Sciences presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
Consolidated Statements of Cash Flows · USD thousands
| USD thousands | FY2025 Year ended Dec 31, 2025 | FY2024 Year ended Dec 31, 2024 | FY2023 Year ended Dec 31, 2023 | FY2022 Year ended Dec 31, 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net loss | (6,261) | (10,086) | (10,830) | (5,549) |
| Adjustments to reconcile net loss to net cash (used in) provided by operating activities: | ||||
| Depreciation and amortization | 4,123 | 4,968 | 5,553 | 5,293 |
| Impairment of goodwill | 0 | 3,861 | 2,284 | — |
| Amortization of operating lease right-of-use assets | 344 | 339 | 349 | 395 |
| Amortization of deferred financing costs and debt discount | 157 | 148 | 140 | 157 |
| Provision for credit losses | 129 | (182) | (110) | 107 |
| Stock-based compensation expense | 643 | 427 | 1,303 | 1,466 |
| Loss on debt extinguishment | — | 0 | 909,000 | — |
| Loss on disposal of property and equipment | 92 | 49 | 72 | 52 |
| Gain on forgiveness of debt | — | — | — | 0 |
| Settlement gains | (1,135) | — | — | — |
| Inventory write-off | 0 | 162 | — | — |
| Deferred income taxes | 0 | (186) | (120) | 40 |
| Changes in operating assets and liabilities: | ||||
| Accounts receivable | 1,003 | (631) | 141 | (1,145) |
| Inventories | (288) | 572 | 689 | (1,524) |
| Prepaid expenses and other assets | (252) | (189) | 246 | (111) |
| Accounts payable | 350 | (954) | (100) | 603 |
| Accrued expenses and other liabilities | (1,248) | 2,266 | (197) | 229 |
| Deferred revenues | (123) | (57) | (472) | (644) |
| Operating lease liabilities | (328) | (319) | (376) | (477) |
| Net cash (used in) provided by operating activities | (2,794) | 188 | (519) | (1,108) |
| Cash flows from investing activities: | ||||
| Purchase of property and equipment | (1,468) | (1,636) | (5,019) | (3,552) |
| Cash paid in connection with TheraClear asset acquisition | — | — | 0 | — |
| TheraClear Corporation | — | — | — | (631,000) |
| RA Medical Systems, Inc. | — | — | — | 0 |
| Net cash used in investing activities | (1,468) | (1,636) | (5,019) | (4,183) |
| Cash flows from financing activities: | ||||
| Proceeds from long-term debt | — | 0 | 7,000,000 | 0 |
| Payment of deferred financing costs | — | 0 | (97,000) | 0 |
| Repayment of note payable | — | — | — | 0 |
| Repayments of long-term debt | — | — | — | 0 |
| Payment of contingent consideration | 0 | (18) | (42) | (500) |
| Sale of common stock, net of offering costs | 3,579 | 1,943 | — | — |
| Net cash provided by financing activities | 3,579 | 1,925 | 6,861 | (500) |
| Net (decrease) increase in cash, cash equivalents and restricted cash | (683) | 477 | 1,323 | (5,791) |
| Cash, cash equivalents and restricted cash at beginning of year | 8,595 | 8,118 | 6,795 | 12,586 |
| Cash, cash equivalents and restricted cash at end of year | 7,912 | 8,595 | 8,118 | 6,795 |
| Supplemental disclosure of cash flow information: | ||||
| Cash paid during the year for interest | 1,811 | 1,973 | 1,415 | 744 |
| Cash paid during the year for income taxes | — | 23,000 | 22,000 | 19,000 |
| Supplemental schedule of non-cash operating, investing and financing activities: | ||||
| Modification of common stock warrants | — | 0 | 384,000 | — |
| Transfer of property and equipment to inventories | 280 | 307 | 267 | 463 |
| Issuance of common stock warrants in connection with Senior Term Facility | — | — | — | 0 |
| Assumed deferred revenues in connection with asset acquisition | — | — | — | 0 |
| Change in intangible assets and fair value of contingent consideration | — | 0 | 7,374,000 | — |
| Accrued equity issuance costs included in accounts payable | 25 | — | — | — |
| Write-off of contingent consideration to settlement gains | 1,176 | — | — | — |
| Write-off of intangible assets to settlement gains | 725 | — | — | — |
| Accrued exit fee recorded as debt discount | 0 | 150 | 450 | — |
| Accrued payment of contingent consideration | 0 | 44 | 18 | — |
| Inventories acquired in connection with TheraClear asset acquisition | — | — | 0 | 71,000 |
| Intangible assets acquired in connection with TheraClear asset acquisition | — | — | 0 | 10,182,000 |
| Contingent consideration issued in connection with TheraClear asset acquisition | — | — | — | 9,122,000 |
| Contingent consideration issued in connection with TheraClear asset | — | — | 0 | — |
| Common stock issued in connection with TheraClear asset acquisition | — | — | 0 | 500,000 |
| Change in operating lease right-of-use assets and liabilities due to new and amended leases | — | — | 0 | 732,000 |
| Operating lease right-of-use assets obtained in exchange for operating lease liabilities | 0 | 977 | — | — |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.